tegafur, Gimeracil and Oteracil Potassium Capsules

DRUG2 trials

Sponsors

LaNova Medicines Zhejiang Co., Ltd., Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Conditions

Malignant Neoplasms of Digestive OrgansResectable Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

RecruitingNCT05934331

LaNova Medicines Zhejiang Co., Ltd.Malignant Neoplasms of Digestive Organs

Start: 2023-07-27End: 2028-07-01Target: 276Updated: 2025-09-12

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07643623

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-15End: 2031-12-31Target: 720Updated: 2026-06-11

Related Papers

Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.

Journal of Clinical Oncology2026-05-27

Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.

Journal of Clinical Oncology2025-05-283 citations